このアイテムのアクセス数: 139

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s41598-022-06513-z.pdf1.31 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorKondo, Takayukien
dc.contributor.authorYamamoto, Tsuyoshien
dc.contributor.authorOkayama, Kaoruen
dc.contributor.authorNarumi, Hidekien
dc.contributor.authorInoue, Haruhisaen
dc.contributor.alternative近藤, 孝之ja
dc.contributor.alternative井上, 治久ja
dc.date.accessioned2022-03-04T07:27:14Z-
dc.date.available2022-03-04T07:27:14Z-
dc.date.issued2022-
dc.identifier.urihttp://hdl.handle.net/2433/268299-
dc.descriptionアルツハイマー病病因分子の産生量に影響を与える土壌微生物叢由来代謝物の同定 --土壌微生物叢 vs アミロイドβから新世代の微生物創薬へ--. 京都大学プレスリリース. 2022-03-02.ja
dc.description.abstractMicrobial flora is investigated to be related with neuropathological conditions in Alzheimer’s disease (AD), and is attracting attention as a drug discovery resource. However, the relevance between the soil microbiota and the pathological condition has not been fully clarified due to the difficulty in isolation culture and the component complexity. In this study, we established a library of secondly metabolites produced in microorganism to investigate the potential effect of microorganisms on the production of amyloid β (Aβ), one of the most representative pathogens of AD. We conducted a library screening to quantify Aβ and neuronal toxicity by using cortical neurons from human induced pluripotent stem cells (iPSCs) of AD patients after adding secondary metabolites. Screening results and following assessment of dose-dependency identified Verrucarin A, produced in Myrothecium spp., showed 80% decrease in Aβ production. Furthermore, addition of Mer-A2026A, produced in Streptomyces pactum, showed increase in Aβ42/40 ratio at the low concentration, and decrease in Aβ production at the higher concentration. As a result, established library and iPSC-based phenotyping assay clarified a direct link between Aβ production and soil microorganisms. These results suggest that Aβ-microorganism interaction may provide insight into the AD pathophysiology with potential therapeutics.en
dc.language.isoeng-
dc.publisherSpringer Natureen
dc.rights© The Author(s) 2022en
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.subjectAlzheimer's diseaseen
dc.subjectHigh-throughput screeningen
dc.subjectInduced pluripotent stem cellsen
dc.subjectPhenotypic screeningen
dc.subjectSoil microbiologyen
dc.titleMetabolites of soil microorganisms modulate amyloid β production in Alzheimer’s neuronsen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleScientific Reportsen
dc.identifier.volume12-
dc.relation.doi10.1038/s41598-022-06513-z-
dc.textversionpublisher-
dc.identifier.artnum2690-
dc.addressCenter for iPS Cell Research and Application (CiRA), Kyoto University; Medical-Risk Avoidance Based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP); iPSC-Based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC)en
dc.addressMicroBiopharm Japan Co., Ltd.en
dc.addressMicroBiopharm Japan Co., Ltd.en
dc.addressMicroBiopharm Japan Co., Ltd.en
dc.addressCenter for iPS Cell Research and Application (CiRA), Kyoto University; Medical-Risk Avoidance Based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP); iPSC-Based Drug Discovery and Development Team, RIKEN BioResource Research Center (BRC); Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospitalen
dc.identifier.pmid35236875-
dc.relation.urlhttps://www.cira.kyoto-u.ac.jp/j/pressrelease/news/220302-190000.html-
dcterms.accessRightsopen access-
datacite.awardNumber17K16121-
datacite.awardNumber20K16599-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17K16121/-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20K16599/-
dc.identifier.eissn2045-2322-
jpcoar.funderName日本学術振興会ja
jpcoar.funderName日本学術振興会ja
jpcoar.awardTitle疾患特異的iPS細胞を用いた3次元創薬プラットフォームの構築ja
jpcoar.awardTitle患者アストロサイトを用いたアルツハイマー病病態の解明ja
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons